Literature DB >> 34355333

PET-Uptake Reduction into Lymph Nodes After Neoadjuvant Therapy is Highly Predictive of Prognosis for Patients Who have Thoracic Esophageal Squamous Cell Carcinoma Treated with Chemoradiotherapy Plus Esophagectomy.

Yushi Nagaki1,2, Satoru Motoyama3,4,5, Yusuke Sato3,4, Akiyuki Wakita3,4, Hiromu Fujita3,4, Kohei Kemuriyama3,4, Yoshihiro Sasaki3,4, Kazuhiro Imai4, Eri Maeda6, Yoshihiro Minamiya4.   

Abstract

BACKGROUND: Patients with 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET)-positive lymph nodes before treatment have a poor prognosis after esophagectomy. This study investigated whether FDG uptake into lymph nodes on FDG-PET (PET-N) during the pre- or posttreatment stage is more predictive of survival for thoracic esophageal squamous cell carcinoma (TESCC) patients who received neoadjuvant chemoradiotherapy (NACRT) followed by esophagectomy.
METHODS: Of 129 TESCC patients with clinical lymphatic metastasis who underwent curative-intent esophagectomy after NACRT between 2010 and 2018, 97 who received PET before and after NACRT were enrolled in the study. The study defined lymph nodes with a maximum standardized uptake value (SUVmax) greater than 2.5 on FDG-PET before NACRT as cPET-N(+) and after NACRT as CRT-cPET-N(+). Both the cPET-N(+) and CRT-cPET-N(-) patients were defined as PET-N responders. Survival was analyzed using the Kaplan-Meier method and Cox proportional hazard models.
RESULTS: No significant difference in survival was detected between the cPET-N(+) and cPET-N(-) patients. However, the CRT-cPET-N(-) patients had significantly better 5-year overall survival (OS) and disease-specific survival (DSS) than the CRT-cPET-N (+) patients. The PET-N responders had significantly better 5-year OS and DSS than the PET-N non-responders, and PET-N response was an independent prognostic factor for 5-year DSS.
CONCLUSION: The PET-N response is a highly predictive prognostic marker for TESCC patients who undergo NACRT followed by esophagectomy. The PET-N response may help clinicians to establish a strategy for perioperative treatments that improves survival for patients with lymph node metastasis in TESCC.
© 2021. Society of Surgical Oncology.

Entities:  

Keywords:  ESCC; Esophagectomy; FDG-PET; NACRT; PET-N

Mesh:

Substances:

Year:  2021        PMID: 34355333     DOI: 10.1245/s10434-021-10564-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  9 in total

1.  Metabolic Rather than Pathological Response to Preoperative Chemoradiotherapy Is a Stronger Predictor of Survival in cStage IIB-IV Esophageal Cancer.

Authors:  Satoru Motoyama; Yusuke Sato; Kiyotomi Maruyama; Shuetsu Usami; Kei Yoshino; Toshinobu Nakatsu; Tomohiko Sasaki; Akiyuki Wakita; Yuta Kawakita; Jiajia Liu; Akira Anbai; Kouichi Ishiyama; Hajime Saito; Yoshihiro Minamiya
Journal:  Anticancer Res       Date:  2017-08       Impact factor: 2.480

2.  Improved detection of individual nodal involvement in squamous cell carcinoma of the esophagus by FDG PET.

Authors:  J Y Choi; K H Lee; Y M Shim; K S Lee; J J Kim; S E Kim; B T Kim
Journal:  J Nucl Med       Date:  2000-05       Impact factor: 10.057

3.  Neoadjuvant Chemoradiotherapy Followed by Esophagectomy with Three-Field Lymph Node Dissection for Thoracic Esophageal Squamous Cell Carcinoma Patients with Clinical Stage III and with Supraclavicular Lymph Node Metastasis.

Authors:  Yusuke Sato; Satoru Motoyama; Yuki Wada; Akiyuki Wakita; Yuta Kawakita; Yushi Nagaki; Kaori Terata; Kazuhiro Imai; Akira Anbai; Manabu Hashimoto; Yoshihiro Minamiya
Journal:  Cancers (Basel)       Date:  2021-02-26       Impact factor: 6.639

4.  FDG PET using SUVmax for preoperative T-staging of esophageal squamous cell carcinoma with and without neoadjuvant chemoradiotherapy.

Authors:  Yung-Cheng Huang; Hung-I Lu; Shun-Chen Huang; Chien-Chin Hsu; Nan-Tsing Chiu; Yu-Ming Wang; Yi-Chun Chiu; Shau-Hsuan Li
Journal:  BMC Med Imaging       Date:  2017-01-05       Impact factor: 1.930

5.  Metabolic parameters of sequential 18F-FDG PET/CT predict overall survival of esophageal cancer patients treated with (chemo-) radiation.

Authors:  Yimin Li; Sebastian Zschaeck; Qin Lin; Sijia Chen; Lili Chen; Hua Wu
Journal:  Radiat Oncol       Date:  2019-02-19       Impact factor: 3.481

6.  SUVmax reduction predicts long-term survival in patients of non-pCR both in the tumor and lymph nodes after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma.

Authors:  Yushi Nagaki; Satoru Motoyama; Yusuke Sato; Akiyuki Wakita; Hiromu Fujita; Yoshihiro Sasaki; Kazuhiro Imai; Yoshihiro Minamiya
Journal:  World J Surg Oncol       Date:  2021-04-09       Impact factor: 2.754

7.  Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of tulathromycin against Haemophilus parasuis in an experimental neutropenic guinea pig model.

Authors:  Yongda Zhao; Li-Li Guo; Binghu Fang; Baotao Liu
Journal:  PLoS One       Date:  2018-12-31       Impact factor: 3.240

8.  Neoadjuvant strategies in resectable carcinoma esophagus: a meta-analysis of randomized trials.

Authors:  Tarun Kumar; Esha Pai; Rajesh Singh; Neville J Francis; Manoj Pandey
Journal:  World J Surg Oncol       Date:  2020-03-21       Impact factor: 2.754

9.  18F- FDG PET/CT-derived parameters predict clinical stage and prognosis of esophageal cancer.

Authors:  Styliani Mantziari; Anastasia Pomoni; John O Prior; Michael Winiker; Pierre Allemann; Nicolas Demartines; Markus Schäfer
Journal:  BMC Med Imaging       Date:  2020-01-22       Impact factor: 1.930

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.